Pipeline - Eloxx Pharmaceuticals

Our Pipeline

Indication

Target

Discovery
/Optimize

IND

Phase I

Phase II

Phase III(Pivotal)

Alport Syndrome (nonsense)

Collagen IV

ELX-02 (SC)

RDEB/JEB (nonsense)

Collagen VII/LAMB3

ZKN013 (oral)

FAP
(nonsense)

APC

ZKN013 (oral)

Class | CF

CFTR

RMA(s)
(oral)

Targeted Oncology

cMYc

RMA
(oral)

Class | CF(inhaled)

CFTR

ELX-02 (inhaled)

Class I CF: Cystic fibrosis patients with nonsense mutations; RDEB/JEB: Recessive Dystrophic/Junctional Epidermolysis Bullosa;FAP: Familial adenomatous polyposis

Learn more about our programs for:

Alport Syndrome

Recessive dystrophic
epidermolysis bullosa (RDEB) /
Junctional epidermolysis bullosa (JEB)

Familial adenomatous
polyposis (FAP) & APC mutant
colorectal cancer (CRC)

DEEP PIPELINE of First-in-class therapies

Our Pipeline

Learn more about our programs for:

DEEP PIPELINE of
First-in-class therapies